Earnings per share for the last twelve months: NAYA Biosciences Inc (NAYA)
Oncology therapy developer NAYA Biosciences (NAYA) faces a lack of stable revenue and a dependence on external capital; therefore, analyzing the chart on GURU.Markets, we find that the current trailing annual EPS value of -30.56 is the current figure. NAYA Biosciences (NAYA) is scaling its clinical portfolio and fertility IT services, leveraging its proprietary antibody creation platform to develop targeted drugs.
Summary analytical data breakdowns for NAYA Biosciences (NAYA)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital NAYA Biosciences|NAYA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio NAYA Biosciences Inc|NAYA - Company Cumulative Debt|Debts to Book Capitalization NAYA Biosciences Inc|NAYA - Company Long-Term Debts|Company Current Liabilities NAYA Biosciences|Quick Ratio nayabiosciences.com
- net income and valuation multiples indicators:
NAYA - Company Net Income|Projected Future Earnings NAYA Biosciences|NAYA - Business Payback Period|Future Price to Earnings nayabiosciences.com|NAYA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NAYA Biosciences|NAYA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) NAYA Biosciences|NAYA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth nayabiosciences.com|NAYA - Expected net earnings per share growth this year|Earnings growth forecast for next year NAYA Biosciences
- revenue and sales proceeds data:
Basic company analysis:nayabiosciences.com (NAYA)
Investors seek a balance between asset valuation and the quality of fundamental indicators. This metric measures the total annual profit distributed per share, excluding the impact of the total issuance volume. For NAYA Biosciences, this calculation reflects the capitalization efficiency of its antibody patent platform. The high intellectual premium of future products must be validated by growth in the rolling annual earnings per share.
Competitors of NAYA Biosciences (NAYA)
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|SBFM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XBIO|Salarius (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Ltd. (PPBT)|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
